LIDDS publishes Prospectus in connection with the Upcoming Rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
UPPSALA, SWEDEN – The Board of Directors of LIDDS AB (publ) (“LIDDS” or the “Company”), has, in connection with the Company’s rights issue that was announced on December 16, 2022 (the “Rights Issue”) prepared an EU Growth Prospectus (the “Prospectus”), which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
Publication of Prospectus
The Prospectus has been prepared in connection with the Rights Issue and has today, January 17, 2023, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions regarding the Rights Issue, is available on LIDDS website (www.liddspharma.com) and Erik Penser Bank’s website (www.penser.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se).
Summary of the Righs Issue
- One (1) existing share in LIDDS held on the record date of January 18, 2023 entitles one (1) subscription right.
- One (1) subscription right entitles for subscription of one (1) newly issued share.
- The subscription price amounts to SEK 1.40 per share
- Trading in subscription rights will take place during the period January 23 – February 1, 2023
- The subscription period runs during the period 23 January – 6 February 2023
The Rights Issue is secured to approximately 95.7 per cent through subscription commitments and guarantee commitments from existing and external parties. If fully subscribed, the Rights Issue brings approximately 48.6 MSEK before issue costs, to the Company. To enable further capital contributions, in the event that the Rights Issue is oversubscribed, the board may exercise an over-allotment option of up to approximately SEK 15.0 million. For further information on the Rights Issue, please refer to the published Prospectus.
Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.
InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod
January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex wil...
InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod
27 januari, 2023 – InDex Pharmaceuticals Holding AB (publ) meddelar idag en uppdatering av tidplanen för valet av dos i den pågående fas III-studien CONCLUDE med läkemedelskandidaten cobitolimod. Utfallet av dosvalet förväntas fjärde kvartalet 2023. Vid den tidpunkten har InDex slutfört bedömning av...
Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2022 at a earnings call on February 3rd at 10:00 CET
The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.menti...